Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

New Company Startup to Launch Genome Information Platform Technology in Japan

By BiotechDaily International staff writers
Posted on 04 Feb 2014
Sony Corp. (Tokyo, Japan) reported that Sony, M3, Inc. (Tokyo, Japan), and Illumina, Inc. (San Diego, CA, USA) have agreed to form a collaboration to launch a genome information platform in Japan.

Sony and M3 will establish a new company with Illumina as a minority investor, by the end of February 2014.

Genome research, which analyzes human genetic data together with medical and other information, has the ability to lead to innovations in identifying the origins of diseases, as well as the development of new pharmaceutical agents and treatment approaches. There is mounting anticipation for new developments in the field of personalized medicine, where drugs or treatments are optimized for the individual patient, and this represents an area where genome research findings are forecast to play an increasingly important role.

The new company’s genome-information platform business will provide a genome analysis service for research institutions and businesses in Japan. It will also aggregate genome data with related information such as medical data to support research in areas where genome data is utilized. The company’s goal will be to contribute to advancements in Japanese customized medicine and healthcare. The extent of its business is expected to extend beyond medical research, to provide a service platform that supports the use of genetic data and medical information for personalized medicine and healthcare services for individual patients.

Tadashi Saito, corporate officer, executive vice president, officer in charge of medical business, Sony Corp., noted, “I’m very excited by the potential of this collaboration to deliver new services and breakthroughs that bring us ever closer to the realization of the personalized medicine and healthcare era. At Sony, we are positioning the medical business as one of our key growth pillars. Together with M3, a Sony Group affiliated company and leader in medical information services, and Illumina, who lead the world in next-generation genome-sequencers, we aim to facilitate genome research that further advances Japanese medical care, and in the future establish a new service platform for the medical industry.”

Itaru Tanimura, representative director of M3, Inc., stated, “The Internet had major impact on our lives. Gene diagnosis and treatment will potentially have the same or even greater influence. The current status of the human genome industry is comparable to the Internet in the early 1990s, when companies such as Google, Amazon, and Facebook had yet to emerge. Going forward, I expect companies and services of this magnitude to also appear in this industry. This three party alliance combines each company’s unique strengths and resources, and together we intend to build a service platform that could not have been realized by others.”

“With the cost of whole genome sequencing falling rapidly, the era of genome-based clinical decisions, personalized medicine, and population health initiatives is on the horizon,” said Jay Flatley, chief executive officer of Illumina. Making use of genomic information for these purposes requires significant data collection and analysis and we are excited to work with Sony and M3 to build a powerful genomic database and lay the groundwork to support population health in Japan.”

P5, Inc. (Tokyo, Japan), which will be the new company’s name, launch is scheduled for end of February 2014, with a capital of JPY 118.75 million.

Related Links:

Sony
M3
Illumina



Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.